



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 13-06-2008

Mr. Yasin Tahir,
Director General, IPO-Pakistan
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 17-5-2008 TO BE PUBLISHED 14-06-2008 THE
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 13-06-2008

To,

Mr. Manzoor Ahmed
Section Officer
Cabinet Secretariat
Cabinet Division
Government of Pakistan
Islamabad

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE WEEKENDING 17-5-2008 TO BE PUBLISHED 13-06-2008 IN THE GAZETTE OF PAKISTAN PART-V.**

Reference to Cabinet Secretariats letter No. 18/IPO/2008/RA-IV, dated 23rd April 2008. A manuscript copy of the weekly notification regarding application filed, application accepted and sealing fee due etc., is enclosed herewith for onward transmission to the Printing Corporation of Pakistan Press for publication in the next issue of the Gazette of Pakistan Part-V.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

515/2008	<u>12-5-2008</u> LIM, Jee Keng James, Singapore (Priority 18-5-07 Singapore)	“Composite cement panel”
516/2008	Mr. Safiullah Pakistani	“Energy production (Electrical and Mechanical)”
517/2008	1. Bayer Healthcare AG, 2. Bayer Schering Pharma AG, Germany (Priority 18-5-07 USA)	“Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis”
518/2008	Bayer CropScience Ag, Germany (Priority 14-5-07 Europe)	“Insecticidal substituted thiourea derivatives”
519/2008	1. Arif Pyarali, 2. Zahra Suleman 3. Sara Moiz Karachi, Pakistan	“Novel tropical dosage form comprising silver nanoparticles and pharmaceutically acceptable excipient”
520/2008	Janssen Pharmaceutica NV., Belgium (Priority 14-5-07 Europe)	“Mono-hydrochloric salts of an inhibitor of histone deacetylase”
521/2008	Merck Patent GmbH, Germany (Priority 12-7-07 Germany)	“S. specification”
522/2008	<u>13-5-2008</u> Asst. Prof. Ahmed Sohail (NUST) Islamabad Pakistan	“Solar Industrial Water Heating System”
523/2008	1. AstraZeneca AB, Sweden 2. Argenta Discovery Ltd. United Kingdom	“New compounds 273”
524/2008	Boehringer Ingelheim International GmbH, Germany, (Priority 16-5-07 Europe)	“Dispensing device”

525/2008	Boehringer Ingelheim International GmbH, Germany, (Priority 16-5-07 Europe)	“Dispensing device”
526/2008	Boehringer Ingelheim International GmbH, Germany, (Priority 16-5-07 Europe)	“Dispensing device”
527/2008	Boehringer Ingelheim International GmbH, Germany, (Priority 16-5-07 Europe)	“Dispensing device”
528/2008	Boehringer Ingelheim International GmbH, Germany, (Priority 16-5-07 Europe)	“Dispensing device”
529/2008	Boehringer Ingelheim International GmbH, Germany, (Priority 16-5-07 Europe)	“Dispensing device”
530/2008	Boehringer Ingelheim International GmbH, Germany, (Priority 16-5-07 Europe)	“Dispensing device”
531/2008	Boehringer Ingelheim International GmbH, Germany, (Priority 16-5-07 Europe)	“Dispensing device”
532/2008	Wyeth, USA (Priority 15-5-07 USA)	“Aminoazacyclyl-3- sulfonylindazoles as 5- hydroxytryptamine-6-ligands”
533/2008	Celanese International Corporation, USA (Priority 17-5-07 USA)	“Method and apparatus for making acetic acid with improved light ends column productivity”
534/2008	Eli Lilly and Company, USA (Priority 16-5-07 USA)	“Triazolyl aminopyrimidine compounds”

535/2008	Otsuka Pharmaceutical Co., Ltd. Japan (Priority 15-5-07 USA)	“Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival”
536/2008	Eli Lilly and Company, USA (Priority 16-5-07 USA)	“Triazolyl aminopyrimidine compounds”
	<u>14-5-2008</u>	
537/2008	1. AstraZeneca AB, Sweden 2. Astex Therapeutics Limited, United Kingdom (Priority 15-5-07 USA)	“New compounds 835”
538/2008	1. AstraZeneca AB, Sweden 2. Astex Therapeutics Limited, United Kingdom (Priority 15-5-07 USA)	“New compounds 834”
539/2008	Unidelta S.p.A., Italy, (Priority 07-6-07 Italy)	“Tube connector”
540/2008	Hesco Bastion Limited, England (Priority 15-5-07 GB)	“Protective shelter”
541/2008	Glaxo Group Limited, United Kingdom (Priority 23-12-04 GB) Divisional	“Compounds”
542/2008	Honda Motor Co. Ltd., Japan (Priority 16-5-07 Japan)	“Piping installation structure for vehicle”
	<u>15-5-2008</u>	
543/2008	Bigtec Private Limited, India (Priority 16-5-07 India)	“Recombinant human insulin and a process thereof”
544/2008	Glaxo Group Limited, Great Britain (Priority 24-11-05 GB)	“Hydrochloride salt and hydrate of (E)-2-(5-chloro-2-thienyl)-N-[(3S)-2-oxo-1-(2,3,4,5,-tetrahydro-1H-2-

Divisional

benzazepin-7-yl)-3-pyrrolidinyl)
ehenesulfonamide”

16-5-2008

- | | | |
|-------------------------|---|---|
| 545/2008 | TTI Ellebeau, Inc.,
Japan
(Priority 18-5-07 USA) | “Systems, devices, and methods for passive transdermal delivery of active agents to a biological interface” |
| 546/2008 | Otsuka Pharamaceutical
Factory, Inc.
Japan | “Lipoprotein lipase-activating compositions and benzene compounds” |
| 547/2008 | Lenzing Fibers Limited,
United Kingdom
(Priority 20-10-04 GB) | “Undyed fibrous product comprising both cotton fibres and man-made cellulose fibres” |
| Divisional | | |
| 548/2008 | Amurrio Ferrocarril Y
Equipos, S. A.,
Spain
(Priority 18-5-07 Spain) | “Interlocking system for turnout switch points in railways” |
| 549/2008 | SmithKline Beecham
Corporation,
USA
(Priority 18-5-07 USA) | “Quinoline derivatives as p13 kinase inhibitors” |
| 550/2008 | Wyeth,
USA
(Priority 18-5-07 USA) | “Quinazoline compounds” |
| <u>17-5-2008</u> | | |
| 551/2008 | David Mairs
United Kingdom
(Priority 17-5-07 GB) | “Padlocks” |

~~~~~

## APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.


234/1997 Wyeth  
USA.

“Novel 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]indole  
and pharmaceutical composition thereof”

(INT: CL, C07D 209/90)

139545

The present invention relates to new 2-phenyl-1-[4-(2-aminoethoxy) Benzyl] Indole compound which are useful as estrogenic agent, as well as pharmaceutical composition and method of treatment utilizing these compound, which have the general structures below.




226/1998 Glaxo Group Ltd.  
Great Britain.

“Pyrazine Compound”

(C07D 241/40)

139546

A compound of formula (1)



(1)

Wherein

R<sup>1</sup> is selected from the group consisting of phenyl substituted by one or more halogen atoms, naphthyl and naphthyl substituted by one or more halogen atoms; R<sup>2</sup> is selected from the group consisting of -NH<sub>2</sub> and -NHC(=O)R<sup>a</sup>; R<sup>3</sup> is selected from the group consisting of -NR<sup>b</sup>R<sup>c</sup>, -NHC(=O) R<sup>a</sup> and hydrogen; R<sup>4</sup> is selected from the group consisting of hydrogen, -C<sub>1-4</sub> alkyl, -C<sub>1-4</sub> alkyl substituted by one or more halogen atoms, -CN, -CH<sub>2</sub>OH, -CH<sub>2</sub>OR<sup>d</sup> and -CH<sub>2</sub>S(O)<sub>x</sub>R<sup>d</sup>;

Wherein

R<sup>a</sup> represents C<sub>1-4</sub> alkyl or C<sub>3-7</sub> cycloalkyl, and R<sup>b</sup> and R<sup>c</sup>, which may be the same or different, are selected from hydrogen and C<sub>1-4</sub> alkyl, or together with the nitrogen atom to which they are attached, form a 6 - membered nitrogen containing heterocycle, which heterocycle can be further substituted with one or more C<sub>1-4</sub> alkyl; R<sup>d</sup> is selected from C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkyl substituted by one or more halogen atoms;

666/2000 Agouron  
Pharmaceuticals,  
Inc.  
USA.

“An Indazole Compound”

(C07D 403/02 A61K 31/44)

139547

Indazole compound that modulate and/or inhibit the activity of certain protein kinases are described. These compound and pharmaceutical composition containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical composition containing such compound, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compound.

708/2000 AstraZeneca AB  
Sweden.

“A pharmaceutical composition comprising a pharmaceutically acceptable salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3, 5-dihydroxyhept-6-enoic acid”

(C07D 239/42)

139548

Pharmaceutical composition comprising a pharmaceutically acceptable salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl) amino] pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid as the active ingredient and a tribasic phosphate salt in which the cation is multivalent.

227/2004 Boehringer  
Ingelheim  
Pharmaceuticals  
Inc.  
USA.

“A pharmaceutical composition comprising macrocyclic compound”

(A61K 38/55)

139549

Disclosed are pharmaceutical composition of hepatitis C viral protease inhibitors, and methods of using these composition for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. The composition are lipid based systems and comprise the hepatitis C viral protease inhibitor together with at least one pharmaceutically acceptable amine, at least one pharmaceutically acceptable base, at least one pharmaceutically acceptable oil and optionally one or more additional ingredients.

678/2005 Maschinenfabrik  
Rieter AG.  
Schweiz.

“Transport apron consisting of a rubber or synthetic material for a spinning machine drafting unit”

(D01H 5/86)

139550

A transport apron for a spinning machine drafting unit for transporting a fibre strand to be pneumatically condensed is provided with at least one row of holes extending in transport direction in the manner of a string of beads, which row of holes permits the passage of air. Material which reduces the occurrence of electrostatic charges has been added to the surfaces of the transport apron.

811/2005 Pai Lung  
Machinery Mill  
Co. Ltd.  
Taiwan, R.O.C.

“Fiber blowing and heat dissipating system of single-sided circular knitting machine”

(D04B 35/32)

139551

A fiber blowing and heat dissipating system of single-sided circular knitting machine includes a fixed rod, a revolving supply device, and a fiber blowing device, wherein the revolving supply device includes a fixed rod, a rotary air supply section, and a driving motor. The fixed axle has an air inlet at its top, and the rotary air supply section has an air passage interconnected with the air inlet and connected to the fiber blowing device, such that the driving motor is driven to rotate around the fixed axle to centralize the air flow to blow away the cotton fibers easily produced at a yarn passing eyelet of the yarn passing plate and the yarn feeding eyelet of a yarn feeding nozzle and a knitting needle. The invention also can lower the heat produced by the friction between the rotation of the needle cylinder and the knitting needle.

812/2005      Pai Lung  
Machinery Mill  
Co., Ltd.  
Taiwan, R.O.C.

“Heat dissipating system of high-speed circular knitting machine”

(D04B 35/30)

139552

A heat dissipating system of a high-speed circular knitting machine includes a super low temperature air gun. Cold air is ejected from a cold air outlet of the super low temperature air gun for carrying away the high heat produced by a cylinder base during a knitting process. The super low temperature air gun is connected to an extension pipe and extended to a gap between a cutting disc and a pressing plate, or saddle bases, or a lower rhombus ring and two saddle bases, or yarn feeding nozzles. Cold air ejected from the cold air outlet passes through the gap to the cylinder base or other peripheral components of the high-speed circular knitting machine to achieve the heat dissipating effect. The super low temperature air gun is installed inside a leg for supporting a yarn supplying device or on its external surface or on a yarn feeding ring.

908/2005      1. Mr. Kamran  
Hafeez  
2. Mr. Ikram-e-  
Khuda  
3. Mr. Arif Karim  
4. Mr. Faisal  
Ghazanfar.

“Intelligent Programmable temperature controller”

(G05B 19/045 24/02)

139553

5. Dr. Muhammad  
Yaqub.  
PCSIR. Karachi.

The design of Temperature Controller is presented for utilization as requirements of cooled Incubator. The Incubator is an instrument used for preserving the samples on a pre-defined Temperature. The designed controller is programmable for temperature ranging from 4-to-40°C. The software is designed in assembly language for microcontroller to drive the compressor as well as heater. The logic behind achieving and maintaining the SET-VALUE is unique. Once the PROCESS-VALUE (value of temperature taken from the source) reaches the SET-VALUE (value of temperature given by the operator), compressor is kept on continuously where as the heater switches on/off so that to maintain the PROCESS-VALUE equal to the SET-VALUE. A NON-VOLATILE RAM is incorporated to store the program entered by the operator. In this way the stored features (or PROGRAM) remains saved even power off. The system continuously monitors the excess of temperature if it goes above SET-VALUE and retains it into the memory during heating/cooling control so that it is always available for the operator.

909/2005

1. Faisal Ghazanfar  
2. Arif Karim  
3. Ikram-e-Khuda  
4. kamran hafeez  
5. Dr. Muhammad  
Yaqub.  
PCSIR. Karachi.

“Laboratory Weighing Scale”

(G01G 19/414,19/417 GO6F 17/40)

139554

The design of *Laboratory Weighing Scale* is presented. The design comprises of a Microcontroller, Random access memory (RAM) with backup battery, 12bit ADC (Analog to Digital Converter), Liquid crystal display module and precision instrumentation amplifier. The analog signal from the load cell (sensor) is amplified and then converted into Digital form using Analog to Digital converter (12-bit). The Microcontroller reads the digital signal and after performing mathematical calculations with the calibration and Tare parameters, displays it. The Software, written in assembly language of Microcontroller, is developed for the over all control, processing, and display module handling. The software use 16bit and 32bit mathematical routines for achieving accuracy.

994/2005 Otsuka  
Pharmaceutical  
Factory, Inc.  
Japan.

“Medical Gas Barrier Film “  
(B32B 9/04 A61L31/00)

139555

The present invention intends to provide a gas barrier film suitable for medical uses, which is excellent in gas and vapor properties and can prevent ingredients of an adhesive from eluting even after heating and sterilizing treatment and a medical bag using the gas barrier film. A medical gas barrier film of the present invention comprises a multilayer gas barrier film including a deposition oriented polyester layer having a deposited layer of an inorganic oxide on one surface, an oriented polyamide layer adhered to the surface of the deposited layer and a polyethylene layer adhered to the surface on the opposite side to the adhered surface of the oriented polyamide layer and a multilayer substrate film including a cyclic olefin polymer layer an elastomer layer and a heat sealing layer and the multilayer substrate film is adhered to the other surface on the opposite side of the deposited layer of the deposition oriented polyester layer .

1002/2005 Teijin Twaron  
B.V.  
Netherlands.

“Method for Dissolving PPTA (para-phenylene-terephthalamide) in Sulfuric acid using a Twin Screw extruder”

(C08J 3/02 C08L 77/06)

139556

The invention pertains to a method for dissolving PPTA(Para-Phenylene-Terephthalamide) or copolymers thereof in sulfuric acid using a twin screw extruder having transporting, mixing, and kneading elements comprising an entering zone, an intermediate zone, a mixing zone, a negative transport zone, a degassing zone, and a pressure build-up zone, the method comprising the steps: transporting PPTA or copolymer thereof into the entering zone at a transport capacity low enough as to prevent sulfuric acid entering the entering zone;

- introducing sulfuric acid in the entering or intermediate zone
- essentially fully filling the mixing zone to allow sufficient time to mix and dissolve PPTA or copolymer thereof in the sulfuric acid to obtain a PPTA or copolymer thereof - sulfuric acid solution;
- creating after the mixing zone a negative transport zone to obtain a product lock between the mixing zone and the degassing zone; creating a thin film of the PPTA or copolymer thereof - sulfuric acid solution in the degassing zone to degas the solution; entering the solution into the output pressure build-up zone to partially fill this zone and to leave the twin screw extruder.


910/2006 Wyeth  
USA.

“Salt of Novel 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]indole and Pharmaceutical Composition Thereof”

(C07D 209/90)

139557

The present invention relates to salt of new 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compound which are useful as estrogenic agents, as well as pharmaceutical composition and method of treatment utilizing these compound, which have the general structures below:



1731/2006 Agouron  
Pharmaceuticals,  
Inc.  
USA.

“ Pharmaceutically acceptable Salt of Indazole Compound”

(C07D 403/02 A61K 31/44)

139558

Indazole compound that modulate and/or inhibit the activity of certain protein kinases are described. these compound and pharmaceutical composition containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. the

invention is also directed to the therapeutic or prophylactic use of pharmaceutical composition containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compound.

1067/2007 AstraZeneca AB.  
Sweden.

“A method of producing a stabilized pharmaceutical composition comprising a pharmaceutically acceptable salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid”

(C07D 239/42 )

139559

Pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-salt in which the cation is multivalent”

~~~~~

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139311	Unilever Plc. United Kingdom	299/2005
139312	Pfizer Products Inc. USA	325/2005

(Mrs. Yasmeen Abbasi)
Controller of Patents
Tel: 9215488